Novartis AG’s injectable brolucizumab for treating wet age-related macular degeneration and Celgene Corp./Agios Pharmaceuticals Inc.'s orphan drug enasidenib for acute myeloid leukemia could this week be recommended for approval across the EU.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?